Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025
Champions Oncology (CSBR), a global preclinical and clinical research services provider specializing in oncology solutions, has scheduled its fourth quarter and year-end financial results announcement for Wednesday, July 23, 2025, after market close.
The company will host a conference call at 4:30 P.M. EDT to discuss the results. Investors can join via phone using access code 792442 or listen to the replay within 72 hours through the company's website or by dialing with passcode 52754.
Champions Oncology (CSBR), fornitore globale di servizi di ricerca preclinica e clinica specializzato in soluzioni oncologiche, ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno per mercoledì 23 luglio 2025, dopo la chiusura del mercato.
L'azienda terrà una conference call alle 16:30 EDT per discutere i risultati. Gli investitori potranno partecipare telefonicamente utilizzando il codice di accesso 792442 o ascoltare la registrazione entro 72 ore tramite il sito web della società o componendo il numero con il codice 52754.
Champions Oncology (CSBR), proveedor global de servicios de investigación preclínica y clínica especializado en soluciones oncológicas, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo para el miércoles 23 de julio de 2025, después del cierre del mercado.
La compañía realizará una llamada conferencia a las 4:30 P.M. EDT para discutir los resultados. Los inversionistas pueden unirse por teléfono usando el código de acceso 792442 o escuchar la repetición dentro de las 72 horas a través del sitio web de la empresa o marcando con el código 52754.
Champions Oncology (CSBR)는 종양학 솔루션을 전문으로 하는 글로벌 전임상 및 임상 연구 서비스 제공업체로, 2025년 7월 23일 수요일 장 마감 후 4분기 및 연말 재무 실적 발표를 예정하고 있습니다.
회사는 결과를 논의하기 위해 동부 표준시 기준 오후 4시 30분에 컨퍼런스 콜을 개최할 예정입니다. 투자자들은 접속 코드 792442를 사용하여 전화로 참여하거나 회사 웹사이트에서 72시간 이내에 재방송을 듣거나 비밀번호 52754로 전화하여 청취할 수 있습니다.
Champions Oncology (CSBR), fournisseur mondial de services de recherche préclinique et clinique spécialisé dans les solutions en oncologie, a prévu d’annoncer ses résultats financiers du quatrième trimestre et de l’année complète le mercredi 23 juillet 2025, après la clôture du marché.
L’entreprise tiendra une conférence téléphonique à 16h30 EDT pour discuter des résultats. Les investisseurs peuvent participer par téléphone en utilisant le code d’accès 792442 ou écouter la rediffusion dans les 72 heures via le site web de la société ou en composant le code secret 52754.
Champions Oncology (CSBR), ein globaler Anbieter von präklinischen und klinischen Forschungsdienstleistungen mit Schwerpunkt auf Onkologielösungen, hat die Bekanntgabe der Finanzergebnisse für das vierte Quartal und das Gesamtjahr für Mittwoch, den 23. Juli 2025, nach Börsenschluss geplant.
Das Unternehmen wird um 16:30 Uhr EDT eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können sich telefonisch mit dem Zugangscode 792442 einwählen oder die Aufzeichnung innerhalb von 72 Stunden über die Website des Unternehmens oder mit dem Passwort 52754 anhören.
- None.
- None.
HACKENSACK, NJ / ACCESS Newswire / July 21, 2025 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the quarter and year ended April 30, 2025, on Wednesday, July 23, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 792442. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 52754, or by accessing the investors section of the company's website within 72 hours.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Champions Oncology (CSBR) release Q4 and year-end 2025 earnings?
How can investors join Champions Oncology's Q4 2025 earnings call?
Where can I find the replay of Champions Oncology's Q4 2025 earnings call?
What period will Champions Oncology's earnings report cover?
